Question Everything. See who's reporting it.

Novo Nordisk’s Semaglutide Patent Expires, Spurring Lower-Priced GLP-1 Drugs in India

Source: The Hindu

The story in brief

The March 2026 expiry of Novo Nordisk’s semaglutide patent in India has spurred lower-priced alternatives, expanding access to GLP-1 drugs for chronic weight management. ICMR-INDIAB research highlights India’s significant burden of diabetes, prediabetes, and obesity. The drugs, which mimic the hormone glucagon-like peptide-1, now range from ₹1,300–₹1,800 to ₹14,000–₹27,500 per month, creating new healthcare service demands.

NEWXFree on Android and iPhone. Open in NEWX